Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KH658 gene therapy in neovascular age-related macular degeneration
NCT06825858Phase 1Active, not recruiting
- Sponsor
- Chengdu Origen Biotechnology Co., Ltd.
- Start
- Apr 2025
- Primary completion
- Jan 2027
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 1, open-label trial of KH658 in neovascular age-related macular degeneration (NVAMD) (3 arms), sponsored by Chengdu Origen Biotechnology Co., Ltd. Primary endpoints: Adverse Events at 52 weeks, Serious Adverse Events at 52 weeks and 1 more. Started Apr 2025; status: active, not recruiting.
02
Drugs
KH658
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT06825858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06825858.